D65

Disseminated intravascular coagulation [defibrination syndrome]

## Clinical Overview of Disseminated Intravascular Coagulation (DIC) Disseminated intravascular coagulation (DIC), often referred to as defibrination syndrome or consumptive coagulopathy, is a complex, life-threatening systemic thrombohemorrhagic disorder. It is never a primary disease but rather a secondary clinico-pathological syndrome that occurs in response to a variety of severe underlying conditions. The hallmark of DIC is the widespread, uncontrolled activation of the coagulation system, leading to the intravascular formation of fibrin and the subsequent occlusion of small and medium-sized vessels. This systemic microvascular thrombosis can lead to multi-organ dysfunction syndrome (MODS), while the simultaneous exhaustion of platelets and coagulation factors (consumption) results in a high risk for severe, spontaneous hemorrhage. ### Pathophysiology The fundamental mechanism of DIC involves the excessive exposure of tissue factor (TF) to the systemic circulation. In conditions like sepsis, inflammatory cytokines (such as tumor necrosis factor-alpha and interleukin-6) stimulate monocytes and endothelial cells to express TF, which then binds with Factor VIIa to trigger the extrinsic coagulation pathway. This leads to massive thrombin generation. Normally, thrombin is regulated by natural anticoagulants like antithrombin III, the protein C system, and tissue factor pathway inhibitor (TFPI). However, in DIC, these regulatory pathways are overwhelmed or inactivated. Furthermore, fibrinolysis—the process of breaking down clots—is initially activated but later suppressed by high levels of plasminogen activator inhibitor-1 (PAI-1), which exacerbates the deposition of fibrin in the microvasculature. ### Clinical Presentation and Diagnosis DIC can present in an acute, fulminant form (often associated with sepsis or trauma) or a chronic, compensated form (often associated with solid tumors). Acute DIC is characterized by both thrombotic manifestations, such as digital ischemia, skin necrosis (purpura fulminans), and renal failure, and hemorrhagic manifestations, such as oozing from venipuncture sites, mucosal bleeding, and gastrointestinal hemorrhage. Diagnosis relies on a combination of clinical suspicion and laboratory findings. Common lab markers include profound thrombocytopenia, prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), significantly elevated D-dimer levels, and decreased fibrinogen. The International Society on Thrombosis and Haemostasis (ISTH) provides a validated scoring system to assist in the diagnosis of overt DIC. ### Management and Prognosis The primary management strategy for DIC is the aggressive treatment of the underlying cause (e.g., broad-spectrum antibiotics for sepsis, delivery for placental abruption, or chemotherapy for malignancy). Without addressing the trigger, hematologic support is often futile. Supportive care includes the judicious use of blood products: platelet transfusions for severe thrombocytopenia, fresh frozen plasma (FFP) for prolonged PT/aPTT in the setting of bleeding, and cryoprecipitate if fibrinogen levels fall below 100 mg/dL. Anticoagulation with heparin is generally reserved for cases where thrombosis predominates, such as digital ischemia or certain malignancies. Prognosis depends heavily on the severity of the triggering event and the rapid onset of supportive care.

Clinical Symptoms

  • Oozing from surgical sites or IV catheters
  • Petechiae and purpura
  • Ecchymosis (easy bruising)
  • Epistaxis (nosebleeds)
  • Gingival bleeding
  • Hematuria (blood in urine)
  • Hematemesis or melena
  • Digital ischemia or gangrene
  • Acute kidney injury (oliguria/anuria)
  • Respiratory distress or hypoxemia
  • Altered mental status or delirium
  • Purpura fulminans

Common Causes

  • Sepsis (most common, especially Gram-negative bacteria)
  • Severe trauma (crush injuries, traumatic brain injury)
  • Abruptio placentae
  • Amniotic fluid embolism
  • Acute promyelocytic leukemia (APL)
  • Metastatic adenocarcinoma
  • Severe liver disease
  • Vascular malformations (e.g., Kasabach-Merritt syndrome)
  • Venomous snake bites
  • Severe transfusion reactions (hemolytic)
  • Major burns

Documentation & Coding Tips

Link the Underlying Etiology and Document Clinical State

Example: Patient presenting with septic shock secondary to E. coli bacteremia (A41.51) now demonstrating clinical evidence of acute disseminated intravascular coagulation (D65). Noted diffuse petechiae and oozing from IV sites. Labs reveal profound hypofibrinogenemia (60 mg/dL) and thrombocytopenia (20k). Billing Focus: Manifestation/Etiology sequencing. Risk Adjustment: DIC serves as a Major Complication or Comorbidity (MCC), significantly impacting MS-DRG weight and HCC scores.

Billing Focus: Identify the primary cause (sepsis, malignancy, trauma) and sequence D65 as a secondary diagnosis.

Document Consumption vs. Fibrinolysis Components

Example: Secondary DIC (D65) confirmed in the setting of abruptio placentae (O45.91). Evidence of consumptive coagulopathy with fibrinogen depletion and elevated fibrin degradation products (FDPs). Initiated cryoprecipitate and FFP transfusion protocol. Billing Focus: Specify the acuity (acute vs chronic, though D65 covers both). Risk Adjustment: Reflects acute critical illness and multisystem organ dysfunction.

Billing Focus: Use clinical terminology such as 'consumptive coagulopathy' to support the D65 diagnosis.

Distinguish from Isolated Coagulopathy or Thrombocytopenia

Example: Patient with metastatic adenocarcinoma of the prostate (C61) presenting with chronic, compensated disseminated intravascular coagulation (D65). Noted mild thrombocytopenia and borderline elevated PT/INR, but without frank hemorrhage. Unlike isolated thrombocytopenia (D69.6), the global activation of clotting is present. Billing Focus: Avoid coding isolated abnormal lab findings (R79.1) when a definitive diagnosis like DIC is established. Risk Adjustment: Chronic DIC in malignancy remains a significant risk factor for HCC mapping.

Billing Focus: Differential coding to ensure D65 is used instead of less specific R-codes for lab abnormalities.

Specify Related Complications like Hemorrhage or Organ Ischemia

Example: Acute DIC (D65) resulting in microvascular thrombosis and subsequent acute kidney injury (N17.9). Patient exhibits gangrenous changes to distal phalanges. Plan includes low-dose heparin to mitigate microthrombosis. Billing Focus: Document the specific organ systems failed due to DIC-induced ischemia. Risk Adjustment: Captures the catastrophic nature of the condition and the need for intensive care monitoring.

Billing Focus: Requires documentation of both the bleeding and the thrombotic manifestations of DIC.

Report Transfusion Requirements and Therapeutic Response

Example: Disseminated intravascular coagulation (D65) refractory to initial FFP; administered 10 units of cryoprecipitate to maintain fibrinogen >100 mg/dL. Ongoing bleeding from surgical drains noted. Billing Focus: Justifies the use of high-cost blood products and specialized hematology consultation. Risk Adjustment: Frequent monitoring and intensive hematologic intervention reflect high clinical complexity.

Billing Focus: Provides supporting evidence for the severity of the D65 diagnosis through treatment intensity.

Relevant CPT Codes

Related Diagnoses

Hierarchy